Content about pharmaceutical

June 15, 2012

Upsher-Smith wins 2012 DIANAs in Branded Pharmaceutical Product Manufacturer and Consumer Product Manufacturer categories.

MAPLE GROVE, Minn. — Upsher-Smith Labs has been named a 2012 winner of the Healthcare Distribution Management Association DIANA Awards. The Distribution Industry Awards for Notable Achievements in Healthcare, known more familiarly as the DIANAs, are awarded each year by HDMA to leading pharmaceutical and consumer product manufacturers.

June 14, 2012

In healthcare technology circles, e-prescribing is among today’s hottest topics. A vital component of patient-centered care, it creates a connectivity platform that encourages collaboration between the physician and pharmacist who are in joint pursuit of an enhanced patient experience.

In healthcare technology circles, e-prescribing is among today’s hottest topics. A vital component of patient-centered care, it creates a connectivity platform that encourages collaboration between the physician and pharmacist who are in joint pursuit of an enhanced patient experience.

June 6, 2012

A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

HYDERABAD, India — A generic drug maker in India and a German pharmaceutical company will collaborate to develop biosimilars.

Dr. Reddy's Labs and Merck KGaA subsidiary Merck Serono announced a partnership to develop biosimilar cancer treatments, most of them monoclonal antibodies, for global markets. Based in Darmstadt, Germany, Merck KGaA operates in the United States under the name EMD to distinguish itself from U.S. drug maker Merck.

May 31, 2012

As the Food and Drug Administration works to finalize draft guidance related to the development of biosimilar products, pharmacy groups recently weighed in with recommendations to facilitate the entry of lower-cost products into the biologic and specialty pharmaceutical markets.

WASHINGTON — As the Food and Drug Administration works to finalize draft guidance related to the development of biosimilar products, pharmacy groups recently weighed in with recommendations to facilitate the entry of lower-cost products into the biologic and specialty pharmaceutical markets.

May 18, 2012

The Drug Store News Group, the Pharmacist Society and Mylan Inc., one of the world's leading generics and specialty pharmaceutical companies, are pleased to announce an exclusive sponsorship to expand membership opportunities at PharmacistSociety.com – an online forum that supports and enhances professional networks for U.S.-based retail pharmacists, professional organizations and pharmacy companies.

PITTSBURGH and NEW YORK — The Drug Store News Group, the Pharmacist Society and Mylan Inc., one of the world's leading generics and specialty pharmaceutical companies, are pleased to announce an exclusive sponsorship to expand membership opportunities at PharmacistSociety.com — an online forum that supports and enhances professional networks for U.S.-based retail pharmacists, professional organizations and pharmacy companies.

May 17, 2012

More than 80% of health plans would require a drug manufacturer to demonstrate a clear clinical benefit compared with current branded and generic treatments in order for its drug to be placed in the plan's formulary, according to a new survey.

NEW YORK — More than 80% of health plans would require a drug manufacturer to demonstrate a clear clinical benefit compared with current branded and generic treatments in order for its drug to be placed in the plan's formulary, according to a new survey.

May 16, 2012

The Food and Drug Administration on Wednesday identified three online products touting "natural" intimacy enhancement that consumers should avoid because they each contain undeclared pharmaceutical ingredients.

SILVER SPRING, Md. — The Food and Drug Administration on Wednesday identified three online products touting "natural" intimacy enhancement that consumers should avoid because they each contain undeclared pharmaceutical ingredients.

The three products include Boost ultra sexual enhancement formula, VMaxx Rx and Firminite.

May 11, 2012

E-prescribing owes a debt of gratitude to meaningful use. Without the Office of the National Coordinator’s inclusion of the capability as a core measure, enabling physician technologies may not have taken off with such vigor. But where MU’s e-prescribing requirements — such as two-way transmissions, complete active medication lists and formulary information — leave off, real innovation — characterized by real-time transactions, automated requests and responses, and Intelligent Routing like Emdeon provides — begins with many valuable benefits for providers, pharmacies and patients.

E-prescribing owes a debt of gratitude to meaningful use. Without the Office of the National Coordinator’s inclusion of the capability as a core measure, enabling physician technologies may not have taken off with such vigor.

May 2, 2012

The 8th annual Armada Specialty Pharmacy Summit officially kicked off in Las Vegas at the Wynn casino resort on Wednesday morning, with early attendance figures showing a 30% increase over 2011, when more than 1,500 executives attended.

LAS VEGAS — The 8th annual Armada Specialty Pharmacy Summit officially kicked off here at the Wynn casino resort on Wednesday morning, with early attendance figures showing a 30% increase over 2011, when more than 1,500 executives attended.

April 25, 2012

Biotech drug maker Amgen is buying a pharmaceutical company based in Turkey, the companies said Wednesday.

THOUSAND OAKS, Calif. — Biotech drug maker Amgen is buying a pharmaceutical company based in Turkey, the companies said Wednesday.

Amgen said it would acquire 95.6% of Istanbul-based Mustafa Nevzat for $700 million in an all-cash deal, saying the purchase would allow it to expand in Turkey and the surrounding region. The company, also known as MN, is a major supplier of injectable drugs in Turkey and, increasingly, an exporter of medicines.

April 25, 2012

The National Community Pharmacists Association has sent a letter to a Senate committee regarding legislation that would reauthorize the Prescription Drug User Fee Act.

ALEXANDRIA, Va. — The National Community Pharmacists Association has sent a letter to a Senate committee regarding legislation that would reauthorize the Prescription Drug User Fee Act.

April 23, 2012

In practical everyday terms, does it matter to the community or health system pharmacist that the Food and Drug Administration is forging ties with other agencies worldwide and becoming more international in its outlook and focus? You bet.

In practical everyday terms, does it matter to the community or health system pharmacist that the Food and Drug Administration is forging ties with other agencies worldwide and becoming more international in its outlook and focus? You bet.

April 13, 2012

The Pharmaceutical Research and Manufacturers of America announced Friday the appointment of Eli Lilly chairman, president and CEO John Lechleiter as PhRMA chairman at its annual meeting.

BOSTON — The Pharmaceutical Research and Manufacturers of America announced Friday the appointment of Eli Lilly chairman, president and CEO John Lechleiter as PhRMA chairman at its annual meeting. The group also elected Celgene president and CEO Robert Hugin as chairman-elect of its board of directors and Pfizer president and CEO Ian Read as board treasurer. Lechleiter replaces Sanofi CEO Christopher Viehbacher as chairman.

April 13, 2012

The Emdeon team always looks forward to the NCPDP Annual Conference. The 2012 version is coming up in early May at the Arizona Biltmore. As expected, NCPDP has done an excellent job in scheduling a large number of important and interesting topics. Emdeon’s Lathe Bigler will be discussing the impact of health information exchanges (HIEs) and accountable care organizations (ACOs) on our industry, and I am scheduled to talk about the industry’s observations and lessons learned regarding the implementation of D.0.

The Emdeon team always looks forward to the NCPDP Annual Conference. The 2012 version is coming up in early May at the Arizona Biltmore. As expected, NCPDP has done an excellent job in scheduling a large number of important and interesting topics. Emdeon’s Lathe Bigler will be discussing the impact of  health information exchanges (HIEs) and accountable care organizations (ACOs) on our industry, and I am scheduled to talk about the industry’s observations and lessons learned regarding the implementation of D.0.

April 12, 2012

Valeant announced that it has acquired a privately owned specialty pharmaceutical company based in the United States.

MONTREAL — Valeant announced that it has acquired a privately owned specialty pharmaceutical company based in the United States.

Pedinol Pharmacal, a podiatry-focused company that has been in business for more than 85 years, was acquired for an undisclosed amount that was said to be 1.5 times sales. Pedinol touted $18 million in revenue last year.

April 4, 2012

Alliance Boots has continued to expand its presence in the global marketplace by opening its 200th store in Thailand.

LONDON — Alliance Boots has continued to expand its presence in the global marketplace by opening its 200th store in Thailand.

The international pharmacy-led health and beauty group said the store — which was inaugurated by executive chairman Stefano Pessina, pharmaceutical wholesale division CEO Ornella Barra and health and beauty division CEO Alex Gourlay on Tuesday — is located in central Bangkok. Alliance Boots opened its first Boots store in Thailand in 1997, the company said.

March 29, 2012

With as much as two-thirds of retail pharmacy operators' business tied up in the potential Express Scripts-Medco merger, the National Association of Chain Drug Stores, the National Community Pharmacists Association and nine retail pharmacy companies on Thursday filed a lawsuit challenging the merger.

ALEXANDRIA, Va. — With as much as two-thirds of retail pharmacy operators' business tied up in the potential Express Scripts-Medco merger, the National Association of Chain Drug Stores, the National Community Pharmacists Association and nine retail pharmacy companies on Thursday filed a lawsuit challenging the merger.

March 26, 2012

Impax Labs has partnered with a pharmaceutical research, development, manufacturing and commercial operations company on a multiproduct agreement.

HAYWARD, Calif., and FORT COLLINS, Colo. — Impax Labs has partnered with a pharmaceutical research, development, manufacturing and commercial operations company on a multiproduct agreement.

Impax Labs and Tolmar will develop, supply and distribute alternative dosage form products. The products and terms of the agreement were not disclosed; however, Impax Labs president and CEO Larry Hsu said the new agreement "represents an ideal extension of [our] initial product agreement."

March 26, 2012

The recent Food and Drug Administration public meeting on driving future switch potential by way of the pharmacist and/or health technology sparked some discussion on what’s next.


The recent Food and Drug Administration public meeting on driving future switch potential by way of the pharmacist and/or health technology sparked some discussion on what’s next.


March 21, 2012

Israel-based Teva Pharmaceutical Industries is switching stock exchanges, the company said.

JERUSALEM — Israel-based Teva Pharmaceutical Industries is switching stock exchanges, the company said.

The world's largest generic drug manufacturer — and increasingly a player in branded and specialty drugs — announced Wednesday that it would transfer the listing of its shares from the Nasdaq to the New York Stock Exchange, with plans to start trading on the NYSE on May 30 under its current ticker symbol, "TEVA."

March 6, 2012

AmerisourceBergen on Tuesday announced that it has signed a definitive agreement to purchase World Courier Group, a privately held global specialty transportation and logistics provider for the biopharmaceutical industry, for $520 million in cash.

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday announced that it has signed a definitive agreement to purchase World Courier Group, a privately held global specialty transportation and logistics provider for the biopharmaceutical industry, for $520 million in cash.

March 5, 2012

Are pharmacists the weak link in the drug diversion chain? That’s what the pharmacy benefit management lobby seems to imply in a new and controversial ad campaign that questions whether community pharmacists are doing all they should to halt the illegal flow of narcotics from the legitimate pharmaceutical supply chain to the dealer on the street.

Are pharmacists the weak link in the drug diversion chain? That’s what the pharmacy benefit management lobby seems to imply in a new and controversial ad campaign that questions whether community pharmacists are doing all they should to halt the illegal flow of narcotics from the legitimate pharmaceutical supply chain to the dealer on the street.

February 27, 2012

One of the world's largest pharmaceutical companies has acquired the maker and distributor of Emergen-C products.

NEW YORK — One of the world's largest pharmaceutical companies has acquired the maker and distributor of Emergen-C products.

Pfizer on Monday announced its acquisition of Alacer, a privately held company best known for its vitamin C supplement products. Financial terms of the transaction were not disclosed, but Pfizer did note that the deal would complement its Consumer Healthcare division.

February 23, 2012

A Northern Ireland pharmaceutical company has acquired a chemotherapy agent from Gilead.

SOUDERTON, Pa. — A Northern Ireland pharmaceutical company has acquired a chemotherapy agent from Gilead.

Galen said it has acquired DaunoXome (daunorubicin citrate liposome injection), an anthracycline chemotherapy agent that was first approved in the United States in 1996, and is indicated as a first-line cytotoxic therapy for advanced HIV-associated Kaposi’s sarcoma. Galen said its wholly owned subsidiary, Galen US, will market the drug in the United States. DaunoXome will be made available through wholesalers in the United States.

February 17, 2012

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams.

One of the main plotlines of the big story called the drug industry over the past several years has been the patent cliff, the steady loss of patent protection on blockbuster primary care drugs and subsequent generic competition that has forced many drug companies to find new revenue streams. Much of this has taken place in the form of a gradual shift to specialty drugs for such conditions as cancers and autoimmune disorders, but recent developments have shown that primary care drugs may still have some steam left in them.